Skip to content

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

Paris, France, October 16, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced multiple data presentations at the Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, Germany, October 17-20, 2017.

Please find the full PDF press release attached.


GenSight Biologics
Thomas Gidoin
Chief Financial Officer
+33 (0)1 76 21 72 20
nvestor Relations
Florent Alba
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic

Source: GenSight Biologics